Oncology
2 drugs are in development for Colo-rectal Cancer.
- Companies
- 2
- Clinical trials
- 14
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Colo-rectal Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| ALX2004 | ALX ONCOLOGY HOLDINGS INC (ALXO) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| nc410 | NextCure, Inc. (NXTC) |
About this indication
Colo-rectal Cancer context
Oncology·MeSH: Colonic Neoplasms (D003110)
Prevalence
135.0 / 100K
Incidence
36.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Colo-rectal Cancer?
BioSniper tracks 2 drugs in development for Colo-rectal Cancer across 2 companies.
How many clinical trials target Colo-rectal Cancer?
There are 14 clinical trials targeting Colo-rectal Cancer tracked by BioSniper.
What is the prevalence of Colo-rectal Cancer?
The estimated prevalence of Colo-rectal Cancer is approximately 135.0 per 100,000 population.